Scientific
publications

Our researchers are proud of the contributions they make, in collaboration with our research center partners, to the field of Life Sciences.

Frontiers in Pharmacology April 2022

Inflammation- independent antinociceptive effects of DF2755A, a CXCR1/2 selective inhibitor: a new potential therapeutic treatment for peripheral neuropathy associated to non-ulcerative interstitial cystitis/bladder pain syndrome

Laura Brandolini, Andrea Aramini, Gianluca Bianchini, Anna Ruocco, Riccardo Bertini, Rubina Novelli, Patrizia Angelico, Anna Elisa Valsecchi, Roberto Russo, Vanessa Castelli, Annamaria Cimini and Marcello Allegretti.

ACS Pharmacol. Transl. Sci. April 2022

Natural compounds inhibit SARS-CoV-2 nsp13 unwinding and ATPase enzyme activities

Angela Corona, Krzysztof Wycisk, Carmine Talarico, Candida Manelfi, Jessica Milia, Rolando Cannalire, Francesca Esposito, Philip Gribbon, Andrea Zaliani, Daniela Iaconis, Andrea R. Beccari, Vincenzo Summa, Marcin Nowotny, and Enzo Tramontano

PNAS April 2022

PKD-dependent PARP12-catalyzed mono-ADP-ribosylation of Golgin-97 is required for E-cadherin transport from Golgi to plasma membrane

Giovanna Grimaldi, Angela Filograna, Laura Schembri, Matteo Lo Monte, Rosaria Di Martino, Marinella Pirozzi, Daniela Spano, Andrea R. Beccari, Seetharaman Parashuraman, Alberto Luini, Carmen Valente, and Daniela Corda

Frontiers in Pharmacology March 2022

Tamoxifen Twists Again: On and Off-Targets in Macrophages and Infections

Chiara Sfogliarini, Giovanna Pepe, Arianna Dolce, Sara Della Torre, Maria Candida Cesta, Marcello Allegretti, Massimo Locati and Elisabetta Vegeto

International Journal of Molecular Sciences March 2022

MicroRNAs Expression in response to rhNGF in Epithelial Corneal Cells: Focus on Neurotrophin Signaling Pathway

Chiara Compagnoni, Veronica Zelli, Andrea Bianchi, Antinisca Di Marco, Roberta Capelli, Davide Vecchiotti, Laura Brandolini, Anna Maria Cimini, Francesca Zazzeroni, Marcello Allegretti, Edoardo Alesse and Alessandra Tessitore.

Frontiers in Oncology March 2022

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice

Paola Verachi, Francesca Gobbo, Fabrizio Martelli, Andrea Martinelli, Giuseppe Sarli, Andrew Dunbar, Ross L. Levine, Ronald Hoffman, Maria Teresa Massucci, Laura Brandolini, Cristina Giorgio, Marcello Allegretti and Anna Rita Migliaccio on behalf of Myeloproliferative Neoplasm Research Consortium.

Frontiers in Pharmacology March 2022

Intravitreal administration of rhNGF enhances regenerative processes in a zebrafish model of retinal degeneration

Pasquale Cocchiaro, Vincenzo Di Donato, Davide Rubbini, Rodolfo Mastropasqua, Marcello Allegretti, Flavio Mantelli, Andrea Aramini and Laura Brandolini.

Orphanet Journal of Rare Diseases February 2022

Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy

Emilio Pedrotti, Erika Bonacci, Chiara Chierego, Alessandra De Gregorio, Tiziano Cozzini, Tommaso Brighenti, Grazia Caldarella, Giovanlorenzo Pastore, Adriano Fasolo & Giorgio Marchini

Orphanet Journal of Rare Diseases February 2022

Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?

Alice Bruscolini, Marco Marenco, Giuseppe Maria Albanese, Alessandro Lambiase & Marta Sacchetti

Frontiers in Pharmacology January 2022

Recombinant Human Nerve Growth Factor (Cenegermin)–Driven Corneal Wound Healing Process: An Evidence-Based Analysis

Chiara Bonzano, Sara Olivari, Carlo Alberto Cutolo, Angelo Macrì, Daniele Sindaco, Davide Borroni, Elisabetta Bonzano and Carlo Enrico Traverso.

Publications per author: 57
Citations: 1699
H-index (2015-2016): 39.5
H-index (2017-2018): 42.4
H-index (2019-2020): 51.5

Number of documents to citations ratio

Source: Elsevier Scopus

Weighted number of publications per thematic area

Source: Elsevier Scopus

Close